Document:

exv10w28

 

Exhibit 10.28

Uroplasty, Inc.

2718 Summer Street N.E.

Minneapolis, Minnesota 55413

April 26, 2006

Mr. Sam B. Humphries

7913 Wyoming Court

Bloomington, Minnesota 55438

     Re: Separation Arrangements

Dear Sam:

     This letter is to confirm your resignation as our President and Chief Executive Officer,
effective the close of business today. We understand that you are leaving Uroplasty to become the
President and Chief Executive Officer of HealthTronics, Inc. Of course, we are all disappointed in
your decision, but understand that it is a good opportunity for you.

     In connection with your departure, we wish to confirm the following matters:

1. Your resignation is voluntary on your part and thus not for “good cause” under your employment
agreement. Accordingly, we will pay your base salary, and provide your benefits, through today.
We will provide no severance payments. We agree that no amount is due you through your termination
date on account of the incentive bonus plan under your employment agreement. Upon termination, we
will provide you our standard COBRA notice as to your health insurance continuation rights.

2. Under your January 1, 2005 employment agreement, we granted you 400,000 options to purchase
shares of our Common Stock at an exercise price of $5.19 per share. All of those options are
vested and you have until December 31, 2014 to exercise them. On April 1, 2003, we also granted
your consulting firm, Executive Advisory Group, 50,000 options to purchase shares of our Common
Stock at an exercise price of $2.80 per share. Those options are exercisable through March 31,
2008, subject to earlier lapse as provided by the April 1, 2003 Stock Option Agreement. Finally,
on April 14, 2003 and in connection with your joining the Board, we granted you 30,000 options to
purchase shares of our Common Stock at an exercise price of $2.25 per share. These options are
exercisable through April 14, 2013, if vested. You are currently vested in 18,000 of these
options. You will vest in an additional 6,000 of these options on each of March 31, 2007 and 2008,
but only if you continue in Board service through the applicable vesting date.

3. You agree to remain on the Uroplasty Board of Directors indefinitely and to stand for
re-election at the next annual meeting of stockholders. However, if the Board, by majority vote of
the remaining directors, asks for your resignation, you agree to provide it promptly. Of course,

 

 

Mr. Sam B. Humphries

April 26, 2006

Page 2

you agree to recuse yourself from deliberations and voting on matters, if any, that arise in
the future as to the relationship between HealthTronics and Uroplasty. We remind you of your
continuing fiduciary and confidentiality obligations arising by virtue of your Board participation
and your employment agreement with us.

4. We have mutually discussed the scope of your non-competition agreement with us and its effect on
your planned employment with HealthTronics. You have agreed that the agreement is enforceable by
us. However, based on our discussions, we have determined not to contest your HealthTronics
employment. In return, to avoid misunderstanding as to the scope of your non-competition agreement
(but without limiting its express provisions), you agree that without our prior written consent and
for one year after your departure from Uroplasty, your employment agreement with us will prohibit
you, as the President and Chief Executive Officer of HealthTronics (and, thus, HealthTronics itself
so long as you are employed with it during that one-year period), from:

	 	•	 	engaging (whether directly or indirectly) in the development, manufacturing,
licensing, marketing or distribution of products or services for the diagnosis or
treatment of urinary or fecal voiding dysfunctions (the “Uroplasty Line of
Business”); and
	 
	 	•	 	initiating or entering into any agreement or other arrangement to develop,
manufacture, license, market, distribute or acquire any technology, business or
entity in the Uroplasty Line of Business, or participating in discussions or
providing information relating to or in anticipation of such an agreement or
arrangement.

The above prohibitions do not apply to future discussions or agreements between HealthTronics and
Uroplasty.

5. You agree to provide a copy of this letter to HealthTronics’ in-house counsel before you begin
employment with HealthTronics.

     Sam, we wish you good luck in your new endeavors. We trust that the opportunity will arise
for future beneficial arrangements between HealthTronics and Uroplasty. If this letter correctly
summarizes our agreement, please so indicate by your signature below.

Very truly yours,

	 	 	 	 	 	 	 	 	 
	Uroplasty, Inc.	 	 	 	Agreed to and accepted:	 	 
	 
	 	 	 	 	 	 	 	 
	By

	 	 

Daniel G. Holman,, Chairman
	 	 	 	 

Sam B. Humphriesexv10w29

 

Exhibit 10.29

Uroplasty, Inc.

2718 Summer Street N.E.

Minneapolis, Minnesota 55413

April 26, 2006

Mr. Daniel G. Holman

15512 Boulder Pointe Road

Eden Prairie, Minnesota 55347

     Re: Amendment to Employment and Consulting Agreement dated January 1, 2005

Dear Dan:

     In light of Sam Humphries’ resignation today as President and Chief Executive Officer of
Uroplasty, I am writing to confirm the arrangements by which you have agreed to serve, in a
consulting capacity, as interim President and Chief Executive Officer. This letter is intended to
amend and supplement your Employment and Consulting Agreement (the “Original Agreement”). All
provisions of your Original Agreement not changed by this letter continue in full force and effect.
Capitalized terms not otherwise defined in this letter have the same meaning as in your Original
Agreement.

     We agree as follows:

1. Consulting Duties. You are in the second year of the Term of the Original Agreement.
In addition to your continuing services as a part-time consultant to us with the continuing title
of Chairman, during the term of this letter agreement (the “Special Term”), you agree to serve as
our Interim President and Chief Executive Officer. As such, you shall assist us with strategic
planning, senior management organizational issues (including the identification and engagement of a
replacement President and Chief Executive Officer), board leadership and such other matters as
reasonably requested. During the Special Term, you agree to devote your full business time,
attention and efforts to promote and further our business. You will faithfully adhere to, execute
and fulfill all policies established by our Board of Directors.

2. Consulting Fees. During the Special Term, you will receive a special consulting fee
(the “Special Consulting Fee”) in addition to the consulting fees you are already receiving
pursuant to the Original Agreement. The Special Consulting Fee is $8,333.33 per month of the
Special
Term, payable on the first day of the month. For consulting services during the balance of April
2006, we will prorate the Special Consulting Fee payable at May 1, 2006. We will not withhold
income taxes from the Special Consulting Fee payments, and you will be solely responsible for
payment of all relevant income taxes.

     In addition to the Special Consulting Fee payments above, you will be entitled to a $50,000
cash bonus (the “Bonus”) upon the date that our stockholders’ equity reaches an amount

 

 

at least
$4,000,000 in excess of our stockholders’ equity at March 31, 2006; provided, however, that you
must be providing your special consulting services pursuant to this letter through the milestone
date in order to earn the Bonus. The Bonus is payable within 30 days after achievement of the
milestone.

3. Modification to Non-Competition Arrangements. In consideration of this letter
agreement, Section 4(a) of your Original Agreement (relating to Non-Competition and
Non-Solicitation) is replaced with the following:

     (a) Basic Terms. The Executive will not, during the period the Executive provides
services to the Company and for a period of one (1) year immediately following the termination of
the Executive’s services to the Company for any reason whatsoever, directly or indirectly, for the
Executive or on behalf of or in conjunction with any other person, persons, entity, company,
business, partnership, corporation, limited liability company or limited liability partnership of
whatever nature:

     (i) engage anywhere worldwide (the “Territory”) as an officer, director, shareholder, owner,
partner, joint venturer or in a managerial capacity, whether as an employee, independent
contractor, consultant or advisor or as a sales representative, in the development, manufacturing,
licensing, marketing or distribution of products or services for the diagnosis or treatment of
urinary or fecal voiding dysfunctions (the “Uroplasty Line of Business”) or in any other business
in competition with the Company;

     (ii) initiate or enter into any agreement or other arrangement to develop, manufacture,
license, market, distribute or acquire any technology, business or entity in the Uroplasty Line of
Business, or participate in discussions or provide information relating to or in anticipation of
such an agreement or arrangement;

     (iii) call upon or solicit any person who is at that time within the Territory an employee of
the Company for the purpose or with the intent of enticing such employee away from or out of the
employ of the Company;

     (iv) call upon or solicit any person or entity which is, at that time, or which has been,
within one (1) year prior to that time, a customer or prospective customer (such prospective status
being determined by whether the Company within the prior year solicited such person or entity’s
business) of the Company within the Territory for the purpose of selling products or
services in the Uroplasty Line of Business or otherwise in competition with the Company within
the Territory; or

     (v) call upon or solicit any prospective acquisition candidate, on the Executive’s own behalf
or on behalf of any competitor, which candidate was, to the Executive’s actual knowledge after due
inquiry, either called upon by the Company or for which the Company made an acquisition analysis,
for the purpose of acquiring such entity or its assets.

-2-

 

     Notwithstanding the above, the Executive may acquire as a passive investment not more than two
percent (2%) of the capital stock of a competing business, whose stock is traded on a national
securities exchange or over-the-counter.”

4. Termination of the Special Term. Either you or we may terminate the Special Term on ten
(10) days prior written notice to the other. Currently, we expect the Special Term to end upon our
engagement of a replacement President and Chief Executive Officer. Upon any termination, we will
pay your Special Consulting Fee as though accrued through the end of the month in which the
termination occurs and your Bonus accrued through the actual date of termination. No termination
of the Special Term will affect the Term of the Original Agreement.

     If this letter correctly summarizes our agreement, please so indicate by your signature below.

	 	 	 	 	 	 	 	 	 
	Very truly yours,	 	 	 	Agreed to and accepted:	 	 
	 
	 	 	 	 	 	 	 	 
	Uroplasty, Inc.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 

Daniel G. Holman
	 	 
	 
	 	 	 	 	 	 	 	 
	By
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Thomas E. Jamison, Chairman,	 	 	 	 	 	 
	 

	 	Compensation Committee	 	 	 	 	 	 

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]